EE05021B1 - Enterokattega ravimkoostis ja selle valmistamise meetod - Google Patents

Enterokattega ravimkoostis ja selle valmistamise meetod

Info

Publication number
EE05021B1
EE05021B1 EEP200100033A EEP200100033A EE05021B1 EE 05021 B1 EE05021 B1 EE 05021B1 EE P200100033 A EEP200100033 A EE P200100033A EE P200100033 A EEP200100033 A EE P200100033A EE 05021 B1 EE05021 B1 EE 05021B1
Authority
EE
Estonia
Prior art keywords
enteric
preparation
pharmaceutical composition
coated pharmaceutical
coated
Prior art date
Application number
EEP200100033A
Other languages
English (en)
Estonian (et)
Inventor
Ullah Ismat
J. Wiley Gary
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200100033A publication Critical patent/EE200100033A/xx
Publication of EE05021B1 publication Critical patent/EE05021B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200100033A 1998-07-17 1998-08-06 Enterokattega ravimkoostis ja selle valmistamise meetod EE05021B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11841898A 1998-07-17 1998-07-17
PCT/US1998/016323 WO2000003696A1 (en) 1998-07-17 1998-08-06 Enteric coated pharmaceutical tablet and method of manufacturing

Publications (2)

Publication Number Publication Date
EE200100033A EE200100033A (et) 2002-06-17
EE05021B1 true EE05021B1 (et) 2008-06-16

Family

ID=22378467

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100033A EE05021B1 (et) 1998-07-17 1998-08-06 Enterokattega ravimkoostis ja selle valmistamise meetod

Country Status (35)

Country Link
US (2) US6331316B1 (cs)
EP (1) EP1098635B1 (cs)
JP (1) JP2002520350A (cs)
KR (1) KR100535954B1 (cs)
CN (1) CN1195499C (cs)
AR (1) AR019934A1 (cs)
AT (1) ATE268165T1 (cs)
AU (1) AU750388B2 (cs)
BG (1) BG65443B1 (cs)
BR (1) BR9815948A (cs)
CA (1) CA2337885C (cs)
CO (1) CO5090840A1 (cs)
CZ (1) CZ301557B6 (cs)
DE (1) DE69824319T2 (cs)
DK (1) DK1098635T3 (cs)
EE (1) EE05021B1 (cs)
EG (1) EG23944A (cs)
ES (1) ES2221188T3 (cs)
GE (1) GEP20032912B (cs)
HU (1) HU226492B1 (cs)
ID (1) ID27019A (cs)
IL (1) IL139701A0 (cs)
LT (1) LT4844B (cs)
LV (1) LV12638B (cs)
NO (1) NO330554B1 (cs)
NZ (1) NZ508298A (cs)
PL (1) PL195587B1 (cs)
PT (1) PT1098635E (cs)
RO (1) RO121082B1 (cs)
RU (1) RU2201217C2 (cs)
SK (1) SK285152B6 (cs)
TR (1) TR200003577T2 (cs)
UA (1) UA73092C2 (cs)
WO (1) WO2000003696A1 (cs)
ZA (1) ZA993446B (cs)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6756811B2 (en) * 2000-03-10 2004-06-29 Easic Corporation Customizable and programmable cell array
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
CA2438641A1 (en) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
GB2377874B (en) * 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
GB2379854B (en) * 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
WO2003026630A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell with different shapes
US20030191185A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
US6967218B2 (en) * 2002-01-11 2005-11-22 Biovail Laboratories, Inc. Pravastatin pharmaceutical formulations and methods of their use
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
WO2003072089A1 (en) * 2002-02-21 2003-09-04 Biovail Laboratories Inc. Controlled release dosage forms
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
JP2006504686A (ja) * 2002-09-03 2006-02-09 バイオヴェイル ラボラトリーズ インコーポレイテッド プラバスタチンの医薬品製剤およびそれらの使用方法
MXPA05002899A (es) * 2002-09-16 2005-05-27 Wyeth Corp Formulaciones de liberacion controlada para administracion oral de un agente terapeutico polipeptido y sus metodos de uso.
HUE031650T2 (en) 2002-10-01 2017-07-28 Banner Life Sciences Llc Enterosolvent preparation for soft capsule wall production
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
EP1699442A2 (en) * 2003-12-31 2006-09-13 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
AU2005209843B2 (en) 2004-01-30 2012-02-16 The Johns Hopkins University Nitroxyl progenitor compounds and methods of use
MY145329A (en) * 2004-03-26 2012-01-31 Lek Pharmaceuticals Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
RU2276974C2 (ru) * 2004-07-01 2006-05-27 Некоммерческое партнерство Научно-технический центр "Лекарства и биотехнология" (НТЦ "Лекбиотех") Лекарственное средство "гастропек" для улучшения процессов пищеварения и способ его применения
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
PL1817013T3 (pl) * 2004-11-18 2009-01-30 Bristol Myers Squibb Co Dojelitowa powlekana peletka zawierająca Ixabepilone
WO2006054175A2 (en) * 2004-11-18 2006-05-26 Aurobindo Pharma Limited Stable dosage forms of acid labile drug
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
EP1830886B1 (en) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
CN100398122C (zh) * 2005-01-28 2008-07-02 北京北大药业有限公司 一种治疗颈、腰椎病中药的肠溶包衣组合物
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CA2617051C (en) 2005-07-29 2013-12-17 Stichting Groningen Centre For Drug Research Ph-controlled pulsatile delivery system, methods for preparation and use thereof
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
WO2007016338A2 (en) * 2005-07-29 2007-02-08 Goverment Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Use of chk2 kinase inhibitors for cancer treatment
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
EP1919458B3 (en) 2006-01-27 2017-01-11 The Regents of The University of California Enterically coated cysteamine, cystamine and derivatives thereof
NZ595770A (en) 2006-03-17 2013-04-26 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
WO2008015686A1 (en) * 2006-08-01 2008-02-07 Hetero Drugs Limited Stable multiparticulate formulations of didanosine
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
ES2531002T3 (es) 2007-01-19 2015-03-09 Xcovery Inc Compuestos inhibidores de quinasa
CA2699567C (en) 2007-09-26 2018-01-09 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
ES2331501B1 (es) * 2007-11-14 2010-10-21 Blanver Farmoquimica, Ltda Composicion farmaceutica solida de didanosina.
TWI468167B (zh) * 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
TWI478710B (zh) * 2007-11-30 2015-04-01 Univ California 使用半胱胺產物治療非酒精性脂肪肝炎（ｎａｓｈ）之方法
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
CN104945309B (zh) 2008-05-07 2019-06-04 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其用途
US20090317466A1 (en) * 2008-06-18 2009-12-24 Franco Lori Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine
EP2303018B1 (en) 2008-06-19 2015-10-14 Xcovery Holding Company LLC Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
CA2737257C (en) * 2008-09-18 2016-11-15 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(.epsilon.-caprolactone)
US8729097B2 (en) 2008-10-06 2014-05-20 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
GB2480042B (en) 2009-02-24 2014-03-12 Ritter Pharmaceuticals Inc Solid oral unit-dosage prebiotic forms and methods of use
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
ES2429689T3 (es) * 2009-03-13 2013-11-15 Toyama Chemical Co., Ltd. Tableta y polvo granulado que contienen 6-fluoro-3-hidroxi-2-pirazinocarboxamida
WO2011063339A1 (en) * 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
MX2012006349A (es) * 2009-12-07 2012-10-03 Cardioxyl Pharmaceuticals Inc Derivados de n-aciloxisulfonamida y n-hidroxi-n-acilsulfonamida.
JP5832447B2 (ja) 2009-12-07 2015-12-16 ザ ジョンズ ホプキンス ユニバーシティ ビスアシル化ヒドロキシルアミン誘導体
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2012048259A2 (en) 2010-10-08 2012-04-12 Xcovery Holding Company, Llc Substituted pyridazine carboxamide compounds
WO2013049731A1 (en) * 2011-09-30 2013-04-04 Stomavite Llc A supplement for ostomy patients
CN108409662B (zh) 2011-10-17 2021-10-26 约翰斯霍普金斯大学 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
CN102357088A (zh) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 盐酸二甲双胍肠溶片
CN102526746B (zh) * 2012-02-04 2013-09-18 安徽山河药用辅料股份有限公司 肠溶型水分散体包衣材料的制备方法
JP6306602B2 (ja) 2012-11-01 2018-04-04 ザ ジョンズ ホプキンス ユニバーシティ 分子内環化−脱離による制御されたｈｎｏ放出
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
CN105142627B (zh) 2013-01-18 2019-06-21 卡尔迪奥克斯尔制药公司 包含硝酰基供体的医药组合物
CA3137846A1 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US11452768B2 (en) 2013-12-20 2022-09-27 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
EP3125905A4 (en) 2014-04-04 2017-11-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
WO2015195989A1 (en) 2014-06-20 2015-12-23 Banner Life Sciences Llc Enteric soft capsule compositions
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
CA2970958A1 (en) 2014-12-23 2016-06-30 Cerecor, Inc. Compounds, compositions and methods
RU2668499C2 (ru) * 2015-03-12 2018-10-01 Закрытое Акционерное Общество "Фармфирма "Сотекс" Фармацевтическая композиция в форме таблеток, покрытых кишечнорастворимой оболочкой, и способ ее получения
PE20180670A1 (es) 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
EP4008321A1 (en) 2015-06-09 2022-06-08 Ocuphire Pharma, Inc. Fluorocyclopentenylcytosine for treating tumour
AU2016316056A1 (en) 2015-09-04 2018-02-01 Rexahn Pharmaceuticals, Inc. Quinoxalinyl-piperazinamide methods of use
KR20180093903A (ko) 2015-11-03 2018-08-22 더 브리검 앤드 우먼즈 하스피털, 인크. 음식 알레르기의 치료 및/또는 예방을 위한 치료용 미생물총
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
WO2017173068A1 (en) * 2016-03-30 2017-10-05 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
EP3452095B1 (en) 2016-05-04 2021-04-07 Van den Driessche, Herman Simmondsin formulation
EA201990523A1 (ru) 2016-10-03 2019-10-31 НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3723775A4 (en) 2017-12-15 2022-04-13 Solarea Bio, Inc. MICROBIAL COMPOSITIONS AND METHODS OF TREATING TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
WO2019211492A1 (en) 2018-05-04 2019-11-07 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
FR3083545A1 (fr) 2018-07-04 2020-01-10 Institut National De La Recherche Agronomique Utilisation d'une souche de roseburia intestinalis pour la prevention et le traitement de l'inflammation de l'intestin
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CN117562174A (zh) 2018-11-05 2024-02-20 奇迹生物公司 包含鞣花单宁的微生物组合物及使用方法
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020212822A1 (en) * 2019-04-17 2020-10-22 Amruth Gowda Doddaveerappa Multi-component pharmaceutical single dosage forms and process employed thereof
US20220202818A1 (en) 2019-04-18 2022-06-30 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
EP3986163A2 (en) 2019-06-19 2022-04-27 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
KR20210043779A (ko) * 2019-10-11 2021-04-22 넨시스(주) 판크레아틴 장용코팅 펠릿 제조방법
CN110882228A (zh) * 2019-11-29 2020-03-17 南京禾瀚医药科技有限公司 一种伊匹乌肽肠溶制剂
MX2022007161A (es) * 2019-12-11 2022-07-12 Evonik Operations Gmbh Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad.
CN116249774A (zh) 2020-05-26 2023-06-09 迪奥尼斯治疗公司 核酸人工微型蛋白质组文库
JP2023528479A (ja) 2020-06-05 2023-07-04 ヘンリー フォード ヘルス システム 肺がん及び前立腺がんの治療に使用するダクラタスビル
WO2022140456A1 (en) 2020-12-22 2022-06-30 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
WO2023016321A1 (zh) 2021-08-10 2023-02-16 贝达药业股份有限公司 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2024228542A1 (ko) * 2023-05-04 2024-11-07 풍림무약주식회사 장용성 코팅용 조성물 및 이를 이용한 정제의 제조 방법
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
WO2025101914A1 (en) 2023-11-10 2025-05-15 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors having improved therapeutic index against solid tumors
WO2025126109A1 (en) 2023-12-15 2025-06-19 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4432996A (en) 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
GB8512330D0 (en) 1985-05-15 1985-06-19 Wellcome Found Antiviral compounds
US5254539A (en) 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
AU570853B2 (en) 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US4975283A (en) 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
JP2643222B2 (ja) 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
KR100229754B1 (ko) * 1989-11-24 1999-11-15 샬러 한스, 하우스 한스 루돌프 판크레아틴구형입자, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
CA2098200A1 (en) * 1990-12-21 1992-06-21 William Joseph Kelleher Polyamine drug-resin complexes
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
ATE217188T1 (de) 1992-08-05 2002-05-15 Faulding F H & Co Ltd Granulierte pharmazeutische zusammensetzung
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5789014A (en) 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції

Also Published As

Publication number Publication date
CO5090840A1 (es) 2001-10-30
PL195587B1 (pl) 2007-10-31
HUP0102659A2 (hu) 2002-03-28
CA2337885A1 (en) 2000-01-27
LT4844B (lt) 2001-09-25
SK18832000A3 (sk) 2002-01-07
TR200003577T2 (tr) 2001-06-21
DK1098635T3 (da) 2004-08-09
US6569457B2 (en) 2003-05-27
KR100535954B1 (ko) 2005-12-12
JP2002520350A (ja) 2002-07-09
CN1338925A (zh) 2002-03-06
BG65443B1 (bg) 2008-08-29
HUP0102659A3 (en) 2002-12-28
EP1098635A4 (en) 2002-01-16
NZ508298A (en) 2003-11-28
US6331316B1 (en) 2001-12-18
PL345774A1 (en) 2002-01-02
ATE268165T1 (de) 2004-06-15
PT1098635E (pt) 2004-09-30
ID27019A (id) 2001-02-22
LV12638B (lv) 2001-09-20
CZ301557B6 (cs) 2010-04-14
KR20010070981A (ko) 2001-07-28
EE200100033A (et) 2002-06-17
EP1098635B1 (en) 2004-06-02
LV12638A (lv) 2001-04-20
RO121082B1 (ro) 2006-12-29
EG23944A (en) 2008-01-22
NO330554B1 (no) 2011-05-16
BR9815948A (pt) 2001-02-28
CZ2001215A3 (cs) 2001-10-17
AR019934A1 (es) 2002-03-27
CA2337885C (en) 2008-01-08
AU8898398A (en) 2000-02-07
NO20010260D0 (no) 2001-01-16
UA73092C2 (uk) 2005-06-15
ZA993446B (en) 2000-11-20
DE69824319T2 (de) 2005-08-04
GEP20032912B (en) 2003-03-25
HU226492B1 (en) 2009-03-02
ES2221188T3 (es) 2004-12-16
DE69824319D1 (de) 2004-07-08
AU750388B2 (en) 2002-07-18
RU2201217C2 (ru) 2003-03-27
CN1195499C (zh) 2005-04-06
EP1098635A1 (en) 2001-05-16
SK285152B6 (sk) 2006-07-07
WO2000003696A1 (en) 2000-01-27
US20020051818A1 (en) 2002-05-02
LT2001003A (en) 2001-06-25
IL139701A0 (en) 2002-02-10
BG105203A (bg) 2001-09-28
NO20010260L (no) 2001-03-07

Similar Documents

Publication Publication Date Title
EE05021B1 (et) Enterokattega ravimkoostis ja selle valmistamise meetod
EE04926B1 (et) Enterokattega ravimkoostis ja selle valmistamise meetod
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
FI973733L (fi) Farmaseuttinen valmiste ja menetelmä sen valmistamiseksi
EE04042B1 (et) Suure bioomastatavusega fenofibraatide ravimkoostis ja meetod selle valmistamiseks
FI981034A7 (fi) HD-polyeteenikoostumukset ja menetelmä niiden valmistamiseksi
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
ID27415A (id) Komposisi farmaseutik
EE200000480A (et) Seade ja meetod manustamise toimumise indikatsiooniks
EE03409B1 (et) Kõrge efektiivsusega segusti ja selle valmistamise meetod
EE04739B1 (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ning vaheühend ja selle valmistamismeetod
ID29262A (id) Komposisi farmasi
FI970159L (fi) Ligniinipohjaiset liima-aineet ja menetelmä niiden valmistamiseksi
FI981506A0 (fi) Elastomeerikompositio ja sen valmistusmenetelmä
ID27201A (id) Komposisi farmasi
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
EE04119B1 (et) Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE9900505A (et) Hambaimplantaatsüsteem ja meetod selle valmistamiseks
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE04902B1 (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
EE04770B1 (et) Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine
FI955123A0 (fi) Kolestyramiinia sisältävä koostumus ja menetelmä tämän valmistamiseksi

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231